Valeant Canada announced a significant new investment of $8 million into its Steinbach, Manitoba manufacturing plant, growing its role in manufacturing and exporting important health care products.
The announcement was made today at the BIO International Convention in the presence of the Manitoba Deputy Minister of Growth, Enterprise and Trade, Mr. James B. Wilson. The President of the Life Science Association of Manitoba, Mrs. Tracey Maconachie, was also present at the announcement.
Valeant will complete the transfers of the North American production of Xifaxan and Apriso this year, to its Steinbach facility. These transfers support Valeant’s commitment to Canada as an anchor manufacturing site.
“Since 2012, Valeant has transferred 27 technologies for manufacture at Steinbach, in addition to investing in major improvements to the site in order to maintain competitiveness at the international level,” said Jacques Dessureault, President, Valeant Canada. “It is evidence of our continuing business strategy to grow our Canadian capacity and increase our export sales”.
“The entire biosciences ecosystem in Canada benefits when manufacturing increases here,” said Andrew Casey, President, BIOTECanada. “Through more applied R&D, such as what is happening at the Steinbach facility, the country benefits from the economic and advanced health technology innovation taking place.”
